1. Home
  2. ABTC vs NSPR Comparison

ABTC vs NSPR Comparison

Compare ABTC & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ABTC
  • NSPR
  • Stock Information
  • Founded
  • ABTC 2024
  • NSPR 2005
  • Country
  • ABTC United States
  • NSPR United States
  • Employees
  • ABTC N/A
  • NSPR N/A
  • Industry
  • ABTC EDP Services
  • NSPR Medical/Dental Instruments
  • Sector
  • ABTC Technology
  • NSPR Health Care
  • Exchange
  • ABTC Nasdaq
  • NSPR Nasdaq
  • Market Cap
  • ABTC 122.5M
  • NSPR 99.7M
  • IPO Year
  • ABTC N/A
  • NSPR N/A
  • Fundamental
  • Price
  • ABTC $6.81
  • NSPR $2.42
  • Analyst Decision
  • ABTC
  • NSPR Strong Buy
  • Analyst Count
  • ABTC 0
  • NSPR 2
  • Target Price
  • ABTC N/A
  • NSPR $4.50
  • AVG Volume (30 Days)
  • ABTC 5.6M
  • NSPR 119.2K
  • Earning Date
  • ABTC 11-08-2025
  • NSPR 11-11-2025
  • Dividend Yield
  • ABTC N/A
  • NSPR N/A
  • EPS Growth
  • ABTC N/A
  • NSPR N/A
  • EPS
  • ABTC 2.64
  • NSPR N/A
  • Revenue
  • ABTC $69,890,000.00
  • NSPR $7,066,000.00
  • Revenue This Year
  • ABTC N/A
  • NSPR $7.48
  • Revenue Next Year
  • ABTC N/A
  • NSPR $104.39
  • P/E Ratio
  • ABTC $2.64
  • NSPR N/A
  • Revenue Growth
  • ABTC 6.38
  • NSPR 7.60
  • 52 Week Low
  • ABTC $6.24
  • NSPR $1.99
  • 52 Week High
  • ABTC $14.52
  • NSPR $3.80
  • Technical
  • Relative Strength Index (RSI)
  • ABTC N/A
  • NSPR 49.42
  • Support Level
  • ABTC N/A
  • NSPR $2.38
  • Resistance Level
  • ABTC N/A
  • NSPR $2.57
  • Average True Range (ATR)
  • ABTC 0.00
  • NSPR 0.07
  • MACD
  • ABTC 0.00
  • NSPR 0.01
  • Stochastic Oscillator
  • ABTC 0.00
  • NSPR 31.97

About NSPR InspireMD Inc.

InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.

Share on Social Networks: